Director's Dealing • Mar 8, 2024
Director's Dealing
Open in ViewerOpens in native device viewer
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
(Print or Type Responses)
| 1. Name and Address of Reporting Person Weiss Amir |
2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited TEVA |
5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner |
||||
|---|---|---|---|---|---|---|
| (Last) (First) (Middle) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St., |
3. Date of Earliest Transaction (Month/Day/Year) 03/05/2024 |
Officer (give title below) Other (specify below) Chief Accounting Officer |
||||
| (Street) Tel Aviv, L3 6944020 |
4. If Amendment, Date Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X = Form filed by One Reporting Person Form filed by More than One Reporting Person |
||||
| (City) (Zip) (State) |
| 1.Title of Security | 2. Transaction | 2A. Deemed | 3. Transaction | 4. Securities Acquired | 5. Amount of Securities Beneficially | 7. Nature | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| (Instr. 3) | Date | Execution Date, if Code | (A) or Disposed of (D) Owned Following Reported | Ownership of Indirect | ||||||
| (Month/Day/Year) any | (Instr. 8) | (Instr. 3, 4 and 5) | Transaction(s) | l Form: | Beneficial | |||||
| (Month/Day/Year) | (Instr. 3 and 4) | Direct (D) Ownership | ||||||||
| or Indirect (Instr. 4) | ||||||||||
| (A) or | (1) | |||||||||
| Code | Amount | D) | Price | (Instr. 4) | ||||||
| 'Ordinary Shares (1) | 03/05/2024 | M | 3,564 | A | (2) | 33,314 | D |
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
| 1. Title of | 2 | 3. Transaction | 3A. Deemed | 5. Number 4. |
6. Date Exercisable | 7. Title and Amount 8. Price of 9. Number of | 10 | 11. Nature | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Derivative | Conversion Date | Execution Date, if Transaction of | and Expiration Date | of Underlying | Derivative Derivative | Ownership of Indirect | |||||||||
| Security | or Exercise (Month/Day/Year) any | Code | Derivative | (Month/Day/Year) | Securities | Security | Securities | Form of | Beneficial | ||||||
| (Instr. 3) | Price of | (Month/Day/Year) (Instr. 8) | Securities | (Instr. 3 and 4) | (Instr. 5) | Beneficially | Derivative Ownership | ||||||||
| Derivative | Acquired | Owned | Security: | (Instr. 4) | |||||||||||
| Security | (A) or | Following | Direct (D) | ||||||||||||
| Disposed | Reported | or Indirect | |||||||||||||
| of (D) | Transaction(s) (I) | ||||||||||||||
| (Instr. 3, 4, | (Instr. 4) | (Instr. 4) | |||||||||||||
| and 5) | |||||||||||||||
| Amount | |||||||||||||||
| Or | |||||||||||||||
| Date | Expiration | Title | Number | ||||||||||||
| Exercisable Date | of | ||||||||||||||
| Code | (A) | (D) | Shares | ||||||||||||
| Restricted | Ordinary | ||||||||||||||
| Share | (2) | 03/05/2024 | M | 3,564 | (3) | (3) | Shares | 3,564 | \$ 0 | 3,566 | D | ||||
| Units | (1) |
** Signature of Reporting Person
Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information in this form are not required to respond unless the form displays a currently valid OMB Nuther.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.